Ikgdar 500mg Injection contains Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen found on the surface of B-lymphocytes. Rituximab is indicated for the treatment of various B-cell malignancies, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and certain autoimmune disorders such as rheumatoid arthritis. The mechanism of action involves selective binding to the CD20 antigen, leading to B-cell depletion through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis. Ikgdar 500mg Injection is administered intravenously under strict medical supervision, with dosing regimens tailored to the specific indication and patient response. Prior to infusion, premedication with antihistamines and corticosteroids is recommended to reduce the risk of infusion-related reactions. Patients should be monitored closely for adverse effects, including infusion reactions, infections, and hematologic toxicities. Rituximab therapy requires careful evaluation of patient history, including screening for hepatitis B virus and other infections. The use of Ikgdar 500mg Injection should be reserved for conditions where B-cell depletion is clinically justified, and treatment should be conducted by healthcare professionals experienced in monoclonal antibody therapies. Proper storage and handling are essential to maintain drug stability and efficacy.